<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158009">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01825993</url>
  </required_header>
  <id_info>
    <org_study_id>CIR TAP 2013</org_study_id>
    <secondary_id>2013-000556-17</secondary_id>
    <nct_id>NCT01825993</nct_id>
  </id_info>
  <brief_title>RANDOMISED STUDY OF EPIDURAL VS MPCA MORPHINE VS TAPP IN LAPAROSCOPIC SIGMOIDECTOMY</brief_title>
  <acronym>2013/004</acronym>
  <official_title>RANDOMISED STUDY ABOUT POTSOTERATORY PAIN CONTROL IN LAPAROSCOPIC SIGMOIDECTOMY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators would study the control of postoperative pain with peridural catheter,
      morphine PCA ev or Transabdominal block.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>EVA (POSTOPERATIVE PAIN)</measure>
    <time_frame>72 H POSTOPERATIVE</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The investigators asked the patient the postoperative pain during teh first 72 hours by EVA scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADVERSE EFFECTS</measure>
    <time_frame>five days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the investigators look for adverse effects</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Sigmoidal Tumour</condition>
  <arm_group>
    <arm_group_label>PCA endovenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg/10 min  Morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PERIDURAL CATHETER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peridural L-bupivacaine 0.25%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TANSABDOMINAL BLOCK (TAP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L-BUPIVACAINE im</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-BUPIVACAINE ; MORPHINE</intervention_name>
    <arm_group_label>PERIDURAL CATHETER</arm_group_label>
    <arm_group_label>TANSABDOMINAL BLOCK (TAP)</arm_group_label>
    <other_name>PERIDURAL L-BUPIVACAINE</other_name>
    <other_name>PCA MORPHINE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MORPHINE</intervention_name>
    <arm_group_label>PCA endovenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than 18

          -  Laparoscopic sigmoidectomy

          -  Informed consent firmed

        Exclusion Criteria:

          -  ASA IV

          -  Urgent surgery

          -  Sigmoid tumour stage IV

          -  Cronic pain treatment

          -  No informed consent firmed

          -  Paliative surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PUJOL GEMMA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporacion Parc Tauli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MORA L. LAURA, MD</last_name>
    <phone>34937231010</phone>
    <phone_ext>21490</phone_ext>
    <email>Lmora@tauli.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Corporacion Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Sabadell-Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mora L Laura, MD</last_name>
      <phone>34 937231010</phone>
      <phone_ext>24190</phone_ext>
      <email>Lmora@tauli.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corporacion Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Sabadell-barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MORA L LAURA, MD</last_name>
      <phone>34937231010</phone>
      <phone_ext>21490</phone_ext>
      <email>Lmora@tauli.cat</email>
    </contact>
    <contact_backup>
      <last_name>mora</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 5, 2013</lastchanged_date>
  <firstreceived_date>March 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>LAURA MORA LOPEZ</investigator_full_name>
    <investigator_title>General Surgeon</investigator_title>
  </responsible_party>
  <keyword>Peridural catheter</keyword>
  <keyword>Morphine PCA</keyword>
  <keyword>Transabdominal Block</keyword>
  <keyword>laparoscopic sigmoidectomy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
